Oruka Therapeutics Inc (ORKA)

$35.28 -0.28 (-0.79%)
Market Cap 1.72B
Revenue (ttm) 0.00
Net Income (ttm) -83.72M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 333,500
Avg Vol 549,718
Day's Range N/A - N/A
Shares Out 48.41M
Stochastic %K 77%
Beta -0.38
Analysts Strong Sell
Price Target $56.85

Company Profile

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 1 trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORK...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 606 7910
Website: orukatx.com
Address:
855 Oak Grove Avenue, Suite 100, Menlo Park, United States
NeverFadeTheOracle
NeverFadeTheOracle Feb. 24 at 11:55 PM
$ORKA Derm a great space to be in. 2 of my favorite spaces in Biotech are Pulmonary and Skin
0 · Reply
kshonstocks
kshonstocks Feb. 24 at 7:24 PM
$ORKA higher highs and days hi
0 · Reply
Love_To_Learn
Love_To_Learn Feb. 23 at 12:47 PM
$NCI CREATING BREAKAGE OFF THE 71-7.12 ( 7.23 SEGMENTED AS WELL OLD PET OF MINE COMPARTMENTALIZING THE 7.1-7.12 RANGE FROM OLD ENVB /BEUD 7.07* DR U SHOULD KNOW WHAT THIS IS @zsk78 MY OLD ABIO MOVEMENT NOW $ORKA AND MY 2 DENOMINATOR LEADING CODING THE MM TO ENGAGE AND ACT AFTER MY 2 DENOMINATOR PLACEMENT
0 · Reply
PatternCrawler
PatternCrawler Feb. 18 at 10:07 AM
$ORKA Thinly traded equity requiring patience and strict sizing.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 17 at 2:28 AM
$ORKA RSI: 39.81, MACD: 0.3308 Vol: 1.14, MA20: 33.71, MA50: 31.50 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
thesheiktrader
thesheiktrader Feb. 13 at 2:43 PM
$ORKA this month in 40
0 · Reply
DAOGovernance
DAOGovernance Feb. 4 at 1:47 PM
$ORKA is a mineral exploration company; it is a highly speculative, early-stage play on discovering an economic resource deposit.
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 23 at 11:53 PM
$ORKA Share Price: $34.38 Contract Selected: Aug 21, 2026 $30 Calls Buy Zone: $8.07 – $9.97 Target Zone: $14.87 – $18.17 Potential Upside: 74% ROI Time to Expiration: 209 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 23 at 2:44 PM
$ORKA RSI: 76.85, MACD: 1.4445 Vol: 2.90, MA20: 30.84, MA50: 30.00 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
thesheiktrader
thesheiktrader Jan. 20 at 4:28 PM
$ORKA the day this have trending and volumes we will see a 60-70 stock.
0 · Reply
Latest News on ORKA
Oruka Therapeutics: A Potential Future Psoriasis Play

Feb 25, 2026, 10:03 AM EST - 21 hours ago

Oruka Therapeutics: A Potential Future Psoriasis Play

Oruka Therapeutics to Participate in Multiple Upcoming Conferences

Feb 9, 2026, 7:00 AM EST - 17 days ago

Oruka Therapeutics to Participate in Multiple Upcoming Conferences

Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001

Jan 12, 2026, 7:00 AM EST - 6 weeks ago

Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001

Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026, 7:00 AM EST - 7 weeks ago

Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Oruka Therapeutics: ORKA-001 For Psoriasis In Focus As 2026 Phase 2 Data Nears

Jan 5, 2026, 9:51 PM EST - 7 weeks ago

Oruka Therapeutics: ORKA-001 For Psoriasis In Focus As 2026 Phase 2 Data Nears

Oruka Therapeutics Announces New Board Member and Board Transition

Dec 11, 2025, 4:01 PM EST - 2 months ago

Oruka Therapeutics Announces New Board Member and Board Transition

Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 12, 2025, 4:05 PM EST - 3 months ago

Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oruka Therapeutics to Present at Multiple November Investor Conferences

Oct 29, 2025, 7:00 AM EDT - 4 months ago

Oruka Therapeutics to Present at Multiple November Investor Conferences

Oruka Therapeutics Announces $180 Million Private Placement

Sep 17, 2025, 1:02 AM EDT - 5 months ago

Oruka Therapeutics Announces $180 Million Private Placement

Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001

Sep 17, 2025, 1:00 AM EDT - 5 months ago

Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001

Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 11, 2025, 4:04 PM EDT - 7 months ago

Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September

Jul 21, 2025, 7:00 AM EDT - 7 months ago

Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September

Oruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating Officer

Jul 1, 2025, 4:01 PM EDT - 8 months ago

Oruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating Officer

Oruka Therapeutics to Present at the Jefferies Global Healthcare Conference

May 21, 2025, 7:00 AM EDT - 10 months ago

Oruka Therapeutics to Present at the Jefferies Global Healthcare Conference

Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody

May 20, 2025, 4:01 PM EDT - 10 months ago

Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody

Oruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025, 4:15 PM EDT - 10 months ago

Oruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Oruka Therapeutics to Present at Bank of America Securities 2025 Health Care Conference

Apr 29, 2025, 7:00 AM EDT - 10 months ago

Oruka Therapeutics to Present at Bank of America Securities 2025 Health Care Conference

Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting

Mar 7, 2025, 8:30 AM EST - 1 year ago

Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting

Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 6, 2025, 4:09 PM EST - 1 year ago

Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Oruka Therapeutics to Present at Multiple March Investor Conferences

Feb 19, 2025, 7:00 AM EST - 1 year ago

Oruka Therapeutics to Present at Multiple March Investor Conferences

Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody

Dec 19, 2024, 7:00 AM EST - 1 year ago

Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody

Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)

Dec 18, 2024, 7:00 AM EST - 1 year ago

Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)

Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 13, 2024, 4:25 PM EST - 1 year ago

Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress

Sep 25, 2024, 7:08 AM EDT - 1 year ago

Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress

Oruka Therapeutics Announces $200 Million Private Placement

Sep 12, 2024, 7:05 AM EDT - 1 year ago

Oruka Therapeutics Announces $200 Million Private Placement

ARCA biopharma Announces Completion of Merger with Oruka Therapeutics and Implementation of Reverse Stock Split

Aug 29, 2024, 4:50 PM EDT - 1 year ago

ARCA biopharma Announces Completion of Merger with Oruka Therapeutics and Implementation of Reverse Stock Split

ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics

Aug 26, 2024, 7:30 PM EDT - 1 year ago

ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics

ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics

Aug 23, 2024, 4:30 PM EDT - 1 year ago

ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics

ARCA biopharma Declares Special Dividend in Connection with the Proposed Merger with Oruka Therapeutics

Aug 16, 2024, 4:15 PM EDT - 1 year ago

ARCA biopharma Declares Special Dividend in Connection with the Proposed Merger with Oruka Therapeutics

ARCA biopharma Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 1, 2024, 4:15 PM EDT - 1 year ago

ARCA biopharma Announces Second Quarter 2024 Financial Results and Provides Corporate Update

ARCA BIOPHARMA INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ARCA biopharma, Inc. - ABIO

May 10, 2024, 6:34 PM EDT - 1 year ago

ARCA BIOPHARMA INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ARCA biopharma, Inc. - ABIO

ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update

Apr 25, 2024, 4:15 PM EDT - 1 year ago

ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update

ARCA BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ARCA biopharma, Inc. - ABIO

Apr 5, 2024, 1:27 PM EDT - 2 years ago

ARCA BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ARCA biopharma, Inc. - ABIO

Arca Biopharma stock ($ABIO) soars on merger news

Apr 3, 2024, 11:38 AM EDT - 2 years ago

Arca Biopharma stock ($ABIO) soars on merger news

ARCA biopharma and Oruka Therapeutics Announce Merger Agreement

Apr 3, 2024, 7:30 AM EDT - 2 years ago

ARCA biopharma and Oruka Therapeutics Announce Merger Agreement

ARCA biopharma Announces 2023 Financial Results

Feb 1, 2024, 4:35 PM EST - 2 years ago

ARCA biopharma Announces 2023 Financial Results

ARCA biopharma Announces Third Quarter 2023 Financial Results

Oct 18, 2023, 4:25 PM EDT - 2 years ago

ARCA biopharma Announces Third Quarter 2023 Financial Results

ARCA biopharma Announces Second Quarter 2023 Financial Results

Jul 21, 2023, 4:25 PM EDT - 2 years ago

ARCA biopharma Announces Second Quarter 2023 Financial Results

ARCA biopharma Announces First Quarter 2023 Financial Results

Apr 24, 2023, 4:25 PM EDT - 3 years ago

ARCA biopharma Announces First Quarter 2023 Financial Results

ARCA biopharma Announces 2022 Financial Results and Provides Corporate Update

Feb 24, 2023, 4:20 PM EST - 3 years ago

ARCA biopharma Announces 2022 Financial Results and Provides Corporate Update

James Flynn Joins ARCA biopharma Board of Directors

Dec 19, 2022, 4:05 PM EST - 3 years ago

James Flynn Joins ARCA biopharma Board of Directors

ARCA biopharma Announces Third Quarter 2022 Financial Results

Oct 28, 2022, 4:15 PM EDT - 3 years ago

ARCA biopharma Announces Third Quarter 2022 Financial Results

ARCA biopharma Announces Second Quarter 2022 Financial Results

Aug 2, 2022, 4:15 PM EDT - 3 years ago

ARCA biopharma Announces Second Quarter 2022 Financial Results

Jacob Ma-Weaver Joins ARCA biopharma Board of Directors

Jun 21, 2022, 4:05 PM EDT - 4 years ago

Jacob Ma-Weaver Joins ARCA biopharma Board of Directors

ARCA biopharma Retains Ladenburg Thalmann to Support Strategic Options Review

May 5, 2022, 4:15 PM EDT - 4 years ago

ARCA biopharma Retains Ladenburg Thalmann to Support Strategic Options Review

ARCA biopharma: Activist's Pressure Could Make This Into A Liquidation Play

May 3, 2022, 11:50 AM EDT - 4 years ago

ARCA biopharma: Activist's Pressure Could Make This Into A Liquidation Play

ARCA biopharma Announces First Quarter 2022 Financial Results

May 2, 2022, 4:15 PM EDT - 4 years ago

ARCA biopharma Announces First Quarter 2022 Financial Results

NeverFadeTheOracle
NeverFadeTheOracle Feb. 24 at 11:55 PM
$ORKA Derm a great space to be in. 2 of my favorite spaces in Biotech are Pulmonary and Skin
0 · Reply
kshonstocks
kshonstocks Feb. 24 at 7:24 PM
$ORKA higher highs and days hi
0 · Reply
Love_To_Learn
Love_To_Learn Feb. 23 at 12:47 PM
$NCI CREATING BREAKAGE OFF THE 71-7.12 ( 7.23 SEGMENTED AS WELL OLD PET OF MINE COMPARTMENTALIZING THE 7.1-7.12 RANGE FROM OLD ENVB /BEUD 7.07* DR U SHOULD KNOW WHAT THIS IS @zsk78 MY OLD ABIO MOVEMENT NOW $ORKA AND MY 2 DENOMINATOR LEADING CODING THE MM TO ENGAGE AND ACT AFTER MY 2 DENOMINATOR PLACEMENT
0 · Reply
PatternCrawler
PatternCrawler Feb. 18 at 10:07 AM
$ORKA Thinly traded equity requiring patience and strict sizing.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 17 at 2:28 AM
$ORKA RSI: 39.81, MACD: 0.3308 Vol: 1.14, MA20: 33.71, MA50: 31.50 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
thesheiktrader
thesheiktrader Feb. 13 at 2:43 PM
$ORKA this month in 40
0 · Reply
DAOGovernance
DAOGovernance Feb. 4 at 1:47 PM
$ORKA is a mineral exploration company; it is a highly speculative, early-stage play on discovering an economic resource deposit.
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 23 at 11:53 PM
$ORKA Share Price: $34.38 Contract Selected: Aug 21, 2026 $30 Calls Buy Zone: $8.07 – $9.97 Target Zone: $14.87 – $18.17 Potential Upside: 74% ROI Time to Expiration: 209 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 23 at 2:44 PM
$ORKA RSI: 76.85, MACD: 1.4445 Vol: 2.90, MA20: 30.84, MA50: 30.00 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
thesheiktrader
thesheiktrader Jan. 20 at 4:28 PM
$ORKA the day this have trending and volumes we will see a 60-70 stock.
0 · Reply
fedeblu
fedeblu Jan. 16 at 10:32 PM
$ORKA 34!!!
0 · Reply
blessme1
blessme1 Jan. 16 at 4:34 PM
$ORKA when will the halt up days arrive? Go to 40-50 and the 60s
1 · Reply
fedeblu
fedeblu Jan. 14 at 9:12 PM
$ORKA green by green I hope to reach my personal middle time target of 36 usd
1 · Reply
RunnerSignals
RunnerSignals Jan. 14 at 6:55 PM
$BRCC $APLD $ORKA $VNCE $GLSI Wall Street just nudged the targets higher Which one actually runs next? https://stocksrunner.com/news/2026-01-14-short-term-stocks-with-analyst-stock-upgrades-and-upside-potential
0 · Reply
IN0V8
IN0V8 Jan. 13 at 6:39 PM
$ORKA Watch / Opportunity BTIG raises target price to $73 from $63 Wedbush raises target price to $45 from $42
1 · Reply
fedeblu
fedeblu Jan. 13 at 12:39 PM
$ORKA new target price today of 70!!!
0 · Reply
fedeblu
fedeblu Jan. 12 at 9:11 PM
$ORKA the future seems bright
0 · Reply
Pika_Capital
Pika_Capital Jan. 12 at 8:54 PM
$ORKA should be up way higher after today's data
0 · Reply
outlawinvestor1
outlawinvestor1 Jan. 12 at 12:31 PM
$ORKA 1-2x per year dosing potential. https://ir.orukatx.com/news-releases/news-release-details/oruka-therapeutics-announces-positive-interim-phase-1-data-orka
0 · Reply
fedeblu
fedeblu Jan. 9 at 5:32 PM
$ORKA at 12 someone sold a big order before go lunch…. The answer is strong 👌
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 6 at 1:36 AM
$ORKA Current Stock Price: $26.93 Contracts to trade: $30 ORKA Jan 16 2026 Call Entry: $0.50 Exit: $0.74 ROI: 47% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
garygb
garygb Jan. 5 at 4:15 PM
$ORKA great entry point
0 · Reply